The George Institute For Global Health
United Kingdom


De Z, Renfurm R, Bakris G, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. The lancet. Diabetes & endocrinology. 2018;6:925 - 933. doi:10.1016/S2213-8587(18)30289-4.
Neuen B, Perkovic V. Reducing cardiovascular risk in people with diabetes and kidney disease. The Medical journal of Australia. 2018;209:438 - 439. doi:10.5694/mja18.00929.
Wong M, Heerspink H, Perkovic V. ACCORDION: Ensuring That We Hear the Music Clearly. Clinical journal of the American Society of Nephrology : CJASN. 2018;13:1621 - 1623. doi:10.2215/CJN.11370918.
Rosenstock J, Perkovic V, Johansen O, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA - Journal of the American Medical Association. 2018. doi:10.1001/jama.2018.18269.
Inker L, Grams M, Levey A, et al. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases. 2018. doi:10.1053/j.ajkd.2018.08.013.
Tong A, Manns B, Wang A, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney International. 2018. doi:10.1016/j.kint.2018.08.018.
Matthews D, Perkovic V, Mahaffey K. Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist". Circulation. 2018;138:660 - 661. doi:10.1161/CIRCULATIONAHA.118.035717.
Wong M, Jardine M, Perkovic V. Glucose lowering and the kidney: are all drug classes equal?. The lancet. Diabetes & endocrinology. 2018;6:835 - 837. doi:10.1016/S2213-8587(18)30291-2.
Heerspink H, List J, Perkovic V. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes, Obesity and Metabolism. 2018;20:14 - 18. doi:10.1111/dom.13417.
Haber A, Smyth B, Trongtrakul K, et al. Relative Contributions To Major Dialysis Randomised Controlled Trials From Ten Global Regions. In: NEPHROLOGY; 2018:29 - 29. Available at:
Smyth B, Chan C, Grieve S, et al. Factors Associated With Regression Of Left Ventricular Mass Index In The Active Dialysis Trial. In: NEPHROLOGY; 2018:28 - 28. Available at:
Smyth B, Howard K, Zuo L, et al. Impact Of Extended Hours Dialysis On Utility-Based Quality Of Life: Results From The Active Dialysis Trial. In: NEPHROLOGY; 2018:11 - 12. Available at:
Smyth B, van d, Hong D, et al. The Quality Of Life Improvements Associated With Extended Hours Dialysis Are Consistent Across Subgroups. In: NEPHROLOGY; 2018:28 - 28. Available at:
Heerspink H, Andress D, Bakris G, et al. Baseline characteristics and enrichment results from the SONAR trial. Diabetes, Obesity and Metabolism. 2018;20:1829 - 1835. doi:10.1111/dom.13315.
Okpechi I, Alrukhaimi M, Ashuntantang G, et al. Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology. Kidney International Supplements. 2018;8:27 - 29. doi:10.1016/j.kisu.2017.10.012.
Perkovic V, Neuen B, Ohkuma T, et al. CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Spring Clinical Meeting of the National-Kidney Foundation (NKD). 2018:574 - 574.
De Z, Heerspink H, Jardine M, Perkovic V. Renal trials in diabetes need a platform: time for a global approach?. The Lancet Diabetes and Endocrinology. 2018;6:356 - 358. doi:10.1016/S2213-8587(17)30263-2.
Rådholm K, Wu J, Wong M, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. Diabetes Research and Clinical Practice. 2018;140:118 - 128. doi:10.1016/j.diabres.2018.03.027.
Rosenstock J, Perkovic V, Alexander J, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): A randomized, double-blind, placebo-control. Cardiovascular Diabetology. 2018;17. doi:10.1186/s12933-018-0682-3.
Jardine M, Mahaffey K, Neal B, et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. American Journal of Nephrology. 2018;46:462 - 472. doi:10.1159/000484633.
Heerspink HJL, Perkovic V. Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform. Clin J Am Soc Nephrol. 2018;13(6):946-948. doi:10.2215/CJN.01290118.
Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program. Circulation. 2018. doi:10.1161/CIRCULATIONAHA.118.035901.
Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018. doi:10.1016/S2213-8587(18)30141-4.
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323-334. doi:10.1161/CIRCULATIONAHA.117.032038.
Mohammedi K, Chalmers J, Herrington W, et al. Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutr Diabetes. 2018;8(1):7. doi:10.1038/s41387-017-0012-y.